ATE458736T1 - Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten - Google Patents

Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten

Info

Publication number
ATE458736T1
ATE458736T1 AT04816308T AT04816308T ATE458736T1 AT E458736 T1 ATE458736 T1 AT E458736T1 AT 04816308 T AT04816308 T AT 04816308T AT 04816308 T AT04816308 T AT 04816308T AT E458736 T1 ATE458736 T1 AT E458736T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
pyrroloä2
bupyridine
production
compositions containing
Prior art date
Application number
AT04816308T
Other languages
English (en)
Inventor
Barbara Salom
Anello Matteo D
Maria Brasca
Patrizia Giordano
Katia Martina
Francesco Angelucci
Frederick Brookfield
William Trigg
Edward Boyd
Jonathan Larard
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE458736T1 publication Critical patent/ATE458736T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04816308T 2003-12-24 2004-12-23 Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten ATE458736T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0330043.1A GB0330043D0 (en) 2003-12-24 2003-12-24 Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
PCT/EP2004/014674 WO2005063746A1 (en) 2003-12-24 2004-12-23 PYRROLO[2,3-b]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

Publications (1)

Publication Number Publication Date
ATE458736T1 true ATE458736T1 (de) 2010-03-15

Family

ID=30776535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04816308T ATE458736T1 (de) 2003-12-24 2004-12-23 Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten

Country Status (10)

Country Link
US (2) US7728140B2 (de)
EP (1) EP1701956B1 (de)
JP (2) JP5053642B2 (de)
AT (1) ATE458736T1 (de)
BR (1) BRPI0418184A (de)
CA (1) CA2549898C (de)
DE (1) DE602004025741D1 (de)
ES (1) ES2339456T3 (de)
GB (1) GB0330043D0 (de)
WO (1) WO2005063746A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505552A (ja) * 2002-10-09 2006-02-16 サイオス インク． ｐ３８キナーゼ阻害剤としてのアザインドール系誘導体
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
PT1696920E (pt) * 2003-12-19 2015-01-14 Plexxikon Inc Compostos e métodos para o desenvolvimento de moduladores de ret
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
JP2008503473A (ja) * 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
BRPI0513916A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de pirrol-piridina cinase
CA2589877A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
EP1885723A2 (de) 2005-05-17 2008-02-13 Plexxikon, Inc. Pyrrolo[2,3-b]pyridin-derivative als proteinkinase-hemmer
RS52010B (en) 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
WO2007014707A1 (en) * 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009521490A (ja) * 2005-12-22 2009-06-04 スミスクライン ビーチャム コーポレーション 化合物
PL3091011T3 (pl) 2006-04-07 2018-06-29 Vertex Pharmaceuticals Incorporated Modulatory transporterów posiadających kasetę wiążącą ATP
MX2009002010A (es) 2006-09-06 2009-03-05 Hoffmann La Roche Derivados de heteroarilo como inhibidores de la proteina cinasa.
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
AU2013231026B2 (en) * 2006-11-03 2015-09-17 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2646175T3 (es) * 2006-11-03 2017-12-12 Vertex Pharmaceuticals Incorporated Derivados de azaindol como moduladores de CFTR
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
EP2250172B1 (de) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazin-kinasehemmer
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
EP2414356B1 (de) 2009-04-03 2015-09-02 F.Hoffmann-La Roche Ag Propan-1-sulfonsäure-{3-[5-(4- chlorphenyl)-1h-pyrrolo[2,3-b]pyridin-3-carbonyl]-2,4-difluorphenyl} amidzusammensetzungen und anwendungen davon
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
WO2011060394A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Compounds useful as chemokine receptor antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3381899B1 (de) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Zwischenprodukt für verfahren zur herstellung von cycloalkylcarboxamid-indol-verbindungen
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2872122A1 (de) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmazeutische zusammensetzung aus (r)-1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid und verabreichung
BR112015014752B1 (pt) 2012-12-21 2022-07-05 Plexxikon, Inc Compostos e seus uso para modulação de cinase
MX369174B (es) * 2013-08-22 2019-10-30 Genentech Inc Proceso para la preparación de un compuesto.
RS57476B9 (sr) 2014-04-15 2021-10-29 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
EP3237396B1 (de) * 2014-12-23 2019-07-03 Genfit Heterocyclische derivate als rorgamma-modulatoren
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3740491A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrrolo[2,3-d]pyrimidinverbindungen als ret-kinase-inhibitoren
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CN110872243B (zh) * 2018-08-31 2023-03-31 四川科伦博泰生物医药股份有限公司 磺酰胺类化合物、其制备方法及用途
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN113387831A (zh) * 2020-03-11 2021-09-14 苏州大学 酰胺类化合物及其在制备神经炎症抑制剂中的应用
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CN116438182A (zh) * 2020-10-05 2023-07-14 活力疗法公司 用于抑制bcr-abl酪氨酸激酶的7-氮杂吲哚化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) * 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
JPH08503450A (ja) * 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
TR199902724T2 (xx) 1997-05-03 2000-04-21 Smithkline Beecham P.L.C. Dopamine D3 resept�rleri mod�lat�rleri olarak tetrahidroisokuinolin t�revleri.
EP1041982B1 (de) 1997-12-22 2011-10-19 Bayer HealthCare LLC HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTE HETEROCYCLISCHE HARNSTOFFE
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9821977D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
GB9821978D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
ID28385A (id) 1998-10-08 2001-05-17 Smithkline Beecham Plc Turunan-turunan tetrahidrobenzazepina yang berguna sebagai modulator reseptor d3 dopamina (bahan antipsikotik)
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
ATE323482T1 (de) 1999-07-02 2006-05-15 Stuart A Lipton Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
WO2001081345A1 (fr) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
DE10152306A1 (de) * 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
IL164187A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd 7-Azaindole derivatives and pharmaceutical compositions containing the same
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
ES2339456T3 (es) 2010-05-20
BRPI0418184A (pt) 2007-04-27
DE602004025741D1 (de) 2010-04-08
EP1701956A1 (de) 2006-09-20
WO2005063746A1 (en) 2005-07-14
CA2549898A1 (en) 2005-07-14
JP2012121891A (ja) 2012-06-28
US7728140B2 (en) 2010-06-01
JP2007534653A (ja) 2007-11-29
GB0330043D0 (en) 2004-01-28
US8106069B2 (en) 2012-01-31
JP5053642B2 (ja) 2012-10-17
EP1701956B1 (de) 2010-02-24
CA2549898C (en) 2014-05-27
US20050256151A1 (en) 2005-11-17
US20100210476A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
ATE458736T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten
ATE447571T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
ATE353013T1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
DE60238999D1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
CA2486101A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
PT1427708E (pt) Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
NO20055092L (no) Substituerte pyrimidioner
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
RS20060004A (en) Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
MXPA05008688A (es) Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
NZ765534A (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties